Geode Capital Management LLC Has $948,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Geode Capital Management LLC lifted its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 4.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 803,531 shares of the biotechnology company’s stock after buying an additional 34,032 shares during the quarter. Geode Capital Management LLC owned about 1.03% of CytomX Therapeutics worth $948,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of CTMX. Jacobs Levy Equity Management Inc. raised its stake in CytomX Therapeutics by 1.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 16,359 shares during the last quarter. FMR LLC increased its holdings in CytomX Therapeutics by 17.3% in the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 41,949 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in CytomX Therapeutics by 10.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after buying an additional 26,373 shares during the period. US Bancorp DE bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $40,000. Finally, Assenagon Asset Management S.A. increased its holdings in CytomX Therapeutics by 32.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock valued at $1,940,000 after buying an additional 405,669 shares during the period. 67.77% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Stock Down 10.4 %

CTMX stock opened at $0.88 on Friday. The business has a 50 day moving average price of $1.05 and a two-hundred day moving average price of $1.17. The company has a market cap of $68.88 million, a price-to-earnings ratio of 5.18 and a beta of 1.03. CytomX Therapeutics, Inc. has a twelve month low of $0.83 and a twelve month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.23. The company had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the previous year, the company posted $0.04 EPS. On average, equities research analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a report on Tuesday. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.